CD62L, also known as L-Selectin, LECAM-1, or LAM1, is a cell adhesion molecule on lymphocytes and belongs to the selectin family of proteins
1 . It recognizes sialylated carbohydrate groups and is continuously cleaved from the cell surface by ADAM17. CD62L acts as a homing receptor for lymphocytes to enter secondary lymphoid tissues via high endothelial venules and is commonly found on the cell surface of T cells. Naive T cells and central memory T cells express CD62L to localize in secondary lymphoid organs.
CD62L is continuously endoproteolytically cleaved from the cell surface of CD62L-expressing neutrophils and lymphocytes (shedding). Proteolysis is accelerated, e.g., after antigen activation of T cells
2 .
In clinical trials, a CD62L
+ phenotype of T cells engineered with chimeric antigen receptors (CAR) has been reported to be associated with improved functionality
3 , extended persistence
4 and superior clinical outcome
5 .
The CliniMACS® CD62L Product Line consists of murine anti-CD62L monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD62L Product Line depends on the individual separation strategy. For information on respective capacities, refer to the package insert or contact your local representative.
Please inquire about required CliniMACS System components and accessories.
The CliniMACS
® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for
in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS GMP MicroBeads are for research use and
ex vivo cell processing only.
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.
